USANA Health Sciences (NYSE:USNA) Releases Earnings Results, Misses Expectations By $0.50 EPS

USANA Health Sciences (NYSE:USNA) issued its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50), FiscalAI reports. The firm had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%. USANA Health Sciences updated its FY 2026 guidance to 0.760-0.760 EPS.

USANA Health Sciences Trading Up 0.2%

USANA Health Sciences stock opened at $22.89 on Wednesday. The stock has a 50 day moving average of $20.62 and a two-hundred day moving average of $19.79. USANA Health Sciences has a twelve month low of $16.60 and a twelve month high of $32.32. The stock has a market capitalization of $422.53 million, a price-to-earnings ratio of 48.70, a PEG ratio of 0.90 and a beta of 0.73.

Insider Buying and Selling

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the transaction, the director owned 4,230 shares in the company, valued at approximately $75,843.90. This represents a 36.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The SEC filing for this sale provides additional information. Insiders have sold 17,660 shares of company stock worth $336,579 over the last three months. 0.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in USANA Health Sciences by 1.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after purchasing an additional 21,793 shares during the period. Vanguard Group Inc. increased its position in USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after purchasing an additional 57,249 shares during the period. Dimensional Fund Advisors LP increased its position in USANA Health Sciences by 1.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after purchasing an additional 17,318 shares during the period. Nantahala Capital Management LLC acquired a new position in USANA Health Sciences during the 4th quarter worth approximately $11,485,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of USANA Health Sciences by 22.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 353,946 shares of the company’s stock worth $6,948,000 after buying an additional 65,867 shares in the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on USNA shares. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Finally, Zacks Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, USANA Health Sciences presently has a consensus rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.